August 2, 2019 06:56 AM EDT
R&D

Ko­re­an biotech sees shares blitzed as its on­colyt­ic virus/Nex­avar com­bo fiz­zles in liv­er can­cer

John Carroll

Editor & Founder

An­oth­er Ko­re­an biotech is in trou­ble this morn­ing.

Sil­la­Jen set off shock waves in the sec­tor af­ter they filed no­tice that they are aban­don­ing a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times